The personalized medicine market size has grown rapidly in recent years. It will grow from $422.9 billion in 2025 to $469.11 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, advancements in genetic sequencing, increased healthcare expenditure, growing awareness of personalized medicine, early adoption of digital health solutions.
The personalized medicine market size is expected to see rapid growth in the next few years. It will grow to $733.27 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to integration of ai in diagnostics and therapeutics, expansion of gene and cell therapy products, growing demand for remote patient monitoring, development of precision nutrition solutions, increasing adoption of companion diagnostics. Major trends in the forecast period include personalized genetic profiling, targeted drug development, patient-centric care models, remote health monitoring, lifestyle-based preventive therapies.
The growing obese population is expected to drive growth in the personalized medicine market. Obesity, defined as the abnormal or excessive accumulation of body fat, can significantly impair health. Personalized medicine addresses the specific genetic and molecular factors contributing to obesity, enabling tailored and more effective interventions for individuals. For instance, in December 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, the proportion of women living with obesity in early pregnancy increased from 25.4% in 2022-2023 to 26.2% in 2023-2024. Therefore, the rising prevalence of obesity is contributing to the expansion of the personalized medicine market.
Key companies in the personalized medicine market are investing in technological innovations such as artificial intelligence (AI)-powered platforms to enhance diagnostic accuracy, treatment personalization, and clinical trial efficiency. AI-powered platforms leverage large-scale data analysis to generate actionable insights on disease progression, patient response, and therapeutic outcomes. For instance, in April 2023, OM1, a US-based healthcare company specializing in real-world data and AI, patented an AI-powered platform to accelerate personalized medicine. This platform enables tailored healthcare recommendations, supports informed clinical decision-making, and streamlines clinical trials by efficiently identifying suitable patient candidates. By integrating AI-driven analytics into healthcare workflows, the technology is advancing personalized medicine and driving market growth.
In April 2023, 4D Molecular Therapeutics (4DMT), a US-based clinical-stage gene therapy company developing products for rare and prevalent diseases, acquired worldwide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc. for $140 million. This acquisition represents a significant step forward in personalized medicine for rare and genetic diseases, particularly in treating geographic atrophy, by targeting the complement pathway and potentially improving patient outcomes. Aevitas Therapeutics, Inc., is a US-based biopharmaceutical company focused on developing and commercializing gene therapies for complement-mediated diseases.
Major companies operating in the personalized medicine market are Bayer AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, AstraZeneca plc, Abbott Laboratories, Danaher Corporation, Eli Lilly and Company, Decode Genetics Inc., GE HealthCare Technologies Inc., Roche Diagnostics, Genentech Inc., Biogen Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Myriad Genetics Inc., Verily Life Sciences LLC, Guardant Health Inc., Tempus Labs, Oxford Nanopore Technologies, Foundation Medicine Inc., NanoString Technologies Inc., Exagen Inc., Asuragen Inc., Personal Genome Diagnostics, Precision Biologics Inc., Strata Oncology, Genelex Corp, Invitae Corporation, Color Genomics, Helix OpCo LLC, 10x Genomics Inc., Agena Bioscience Inc., Natera Inc., Becton Dickinson and Company, PerkinElmer Inc., Sophia Genetics, Genomic Vision, Personalis Inc.
North America was the largest region in the personalized medicine market in 2025. Asia-pacific is expected to be the fastest-growing region in the global personalized medicine market during the forecast period. The regions covered in the personalized medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the personalized medicine market by increasing costs for imported diagnostic equipment, genetic sequencing tools, and targeted therapy drugs, particularly impacting Asia-Pacific and North American regions that rely heavily on cross-border supply chains. Oncology, neurology, and rare disease therapeutics segments are most affected due to the high reliance on advanced imported technologies. While tariffs have raised production and operational costs, they have also incentivized local manufacturing and innovation in diagnostics and therapeutics, providing opportunities for regional players to strengthen market presence.
The personalized medicine market research report is one of a series of new reports that provides personalized medicine market statistics, including personalized medicine industry global market size, regional shares, competitors with a personalized medicine market share, detailed personalized medicine market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine industry. This personalized medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Personalized medicine involves customizing medical treatment based on an individual’s genetic, environmental, and lifestyle factors. By considering a person’s unique characteristics, it aims to prevent, diagnose, and treat diseases more effectively, delivering the right therapies to the right patients at the right time.
The main products of personalized medicine include personalized medicine diagnostics, personalized medicine therapeutics, personalized medical care, and personalized nutrition and wellness. Personalized medicine diagnostics involves analyzing an individual’s specific genetic, molecular, and clinical traits to guide disease diagnosis, treatment planning, and management. It is applied in disease diagnosis, treatment selection, monitoring treatment response, and clinical trial enrollment. Key applications of personalized medicine include oncology, neurology, blood transfusion safety, diabetes, autoimmune diseases, cardiology, and others, and it is utilized in hospitals, diagnostic centers, research institutions, academic institutes, and other healthcare settings.
The personalized medicine market consists of sales of topical creams, serums, dietary supplements, customized meal plans, nutritional products, and drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The personalized medicine market size is expected to see rapid growth in the next few years. It will grow to $733.27 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to integration of ai in diagnostics and therapeutics, expansion of gene and cell therapy products, growing demand for remote patient monitoring, development of precision nutrition solutions, increasing adoption of companion diagnostics. Major trends in the forecast period include personalized genetic profiling, targeted drug development, patient-centric care models, remote health monitoring, lifestyle-based preventive therapies.
The growing obese population is expected to drive growth in the personalized medicine market. Obesity, defined as the abnormal or excessive accumulation of body fat, can significantly impair health. Personalized medicine addresses the specific genetic and molecular factors contributing to obesity, enabling tailored and more effective interventions for individuals. For instance, in December 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, the proportion of women living with obesity in early pregnancy increased from 25.4% in 2022-2023 to 26.2% in 2023-2024. Therefore, the rising prevalence of obesity is contributing to the expansion of the personalized medicine market.
Key companies in the personalized medicine market are investing in technological innovations such as artificial intelligence (AI)-powered platforms to enhance diagnostic accuracy, treatment personalization, and clinical trial efficiency. AI-powered platforms leverage large-scale data analysis to generate actionable insights on disease progression, patient response, and therapeutic outcomes. For instance, in April 2023, OM1, a US-based healthcare company specializing in real-world data and AI, patented an AI-powered platform to accelerate personalized medicine. This platform enables tailored healthcare recommendations, supports informed clinical decision-making, and streamlines clinical trials by efficiently identifying suitable patient candidates. By integrating AI-driven analytics into healthcare workflows, the technology is advancing personalized medicine and driving market growth.
In April 2023, 4D Molecular Therapeutics (4DMT), a US-based clinical-stage gene therapy company developing products for rare and prevalent diseases, acquired worldwide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc. for $140 million. This acquisition represents a significant step forward in personalized medicine for rare and genetic diseases, particularly in treating geographic atrophy, by targeting the complement pathway and potentially improving patient outcomes. Aevitas Therapeutics, Inc., is a US-based biopharmaceutical company focused on developing and commercializing gene therapies for complement-mediated diseases.
Major companies operating in the personalized medicine market are Bayer AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, AstraZeneca plc, Abbott Laboratories, Danaher Corporation, Eli Lilly and Company, Decode Genetics Inc., GE HealthCare Technologies Inc., Roche Diagnostics, Genentech Inc., Biogen Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Myriad Genetics Inc., Verily Life Sciences LLC, Guardant Health Inc., Tempus Labs, Oxford Nanopore Technologies, Foundation Medicine Inc., NanoString Technologies Inc., Exagen Inc., Asuragen Inc., Personal Genome Diagnostics, Precision Biologics Inc., Strata Oncology, Genelex Corp, Invitae Corporation, Color Genomics, Helix OpCo LLC, 10x Genomics Inc., Agena Bioscience Inc., Natera Inc., Becton Dickinson and Company, PerkinElmer Inc., Sophia Genetics, Genomic Vision, Personalis Inc.
North America was the largest region in the personalized medicine market in 2025. Asia-pacific is expected to be the fastest-growing region in the global personalized medicine market during the forecast period. The regions covered in the personalized medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the personalized medicine market by increasing costs for imported diagnostic equipment, genetic sequencing tools, and targeted therapy drugs, particularly impacting Asia-Pacific and North American regions that rely heavily on cross-border supply chains. Oncology, neurology, and rare disease therapeutics segments are most affected due to the high reliance on advanced imported technologies. While tariffs have raised production and operational costs, they have also incentivized local manufacturing and innovation in diagnostics and therapeutics, providing opportunities for regional players to strengthen market presence.
The personalized medicine market research report is one of a series of new reports that provides personalized medicine market statistics, including personalized medicine industry global market size, regional shares, competitors with a personalized medicine market share, detailed personalized medicine market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine industry. This personalized medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Personalized medicine involves customizing medical treatment based on an individual’s genetic, environmental, and lifestyle factors. By considering a person’s unique characteristics, it aims to prevent, diagnose, and treat diseases more effectively, delivering the right therapies to the right patients at the right time.
The main products of personalized medicine include personalized medicine diagnostics, personalized medicine therapeutics, personalized medical care, and personalized nutrition and wellness. Personalized medicine diagnostics involves analyzing an individual’s specific genetic, molecular, and clinical traits to guide disease diagnosis, treatment planning, and management. It is applied in disease diagnosis, treatment selection, monitoring treatment response, and clinical trial enrollment. Key applications of personalized medicine include oncology, neurology, blood transfusion safety, diabetes, autoimmune diseases, cardiology, and others, and it is utilized in hospitals, diagnostic centers, research institutions, academic institutes, and other healthcare settings.
The personalized medicine market consists of sales of topical creams, serums, dietary supplements, customized meal plans, nutritional products, and drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Personalized Medicine Market Characteristics
3. Personalized Medicine Market Supply Chain Analysis
4. Global Personalized Medicine Market Trends and Strategies
5. Personalized Medicine Market Analysis of End Use Industries
7. Global Personalized Medicine Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Personalized Medicine Total Addressable Market (TAM) Analysis for the Market
9. Personalized Medicine Market Segmentation
10. Personalized Medicine Market Regional and Country Analysis
11. Asia-Pacific Personalized Medicine Market
12. China Personalized Medicine Market
13. India Personalized Medicine Market
14. Japan Personalized Medicine Market
15. Australia Personalized Medicine Market
16. Indonesia Personalized Medicine Market
17. South Korea Personalized Medicine Market
18. Taiwan Personalized Medicine Market
19. South East Asia Personalized Medicine Market
20. Western Europe Personalized Medicine Market
21. UK Personalized Medicine Market
22. Germany Personalized Medicine Market
23. France Personalized Medicine Market
24. Italy Personalized Medicine Market
25. Spain Personalized Medicine Market
26. Eastern Europe Personalized Medicine Market
27. Russia Personalized Medicine Market
28. North America Personalized Medicine Market
29. USA Personalized Medicine Market
30. Canada Personalized Medicine Market
31. South America Personalized Medicine Market
32. Brazil Personalized Medicine Market
33. Middle East Personalized Medicine Market
34. Africa Personalized Medicine Market
36. Personalized Medicine Market Competitive Landscape and Company Profiles
37. Personalized Medicine Market Other Major and Innovative Companies
40. Personalized Medicine Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Personalized Medicine Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses personalized medicine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for personalized medicine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The personalized medicine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Personalized Medicine Diagnostics; Personalized Medicine Therapeutics; Personalized Medical Care; Personalized Nutrition and Wellness2) By Application: Oncology; Neurology; Blood Transfusion Safety; Diabetes; Autoimmune Diseases; Cardiology; Other Applications
3) By End-use: Hospitals; Diagnostic Centers; Research and Academic Institutes; Other End-Users
Subsegments:
1) By Personalized Medicine Diagnostics: Genetic Testing; Biomarker Testing; Companion Diagnostics; Molecular Imaging2) By Personalized Medicine Therapeutics: Targeted Therapies; Gene Therapies; Monoclonal Antibodies; Cell and Gene Therapy Products
3) By Personalized Medical Care: Tailored Treatment Plans; Patient-Centric Care Models; Digital Health Solutions; Remote Patient Monitoring
4) By Personalized Nutrition And Wellness: Nutrigenomics; Customized Diet Plans; Supplement Personalization; Lifestyle Modification Programs
Companies Mentioned: Bayer AG; Novartis AG; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; AstraZeneca plc; Abbott Laboratories; Danaher Corporation; Eli Lilly and Company; Decode Genetics Inc.; GE HealthCare Technologies Inc.; Roche Diagnostics; Genentech Inc.; Biogen Inc.; Illumina Inc.; Qiagen N.V.; Exact Sciences Corporation; Myriad Genetics Inc.; Verily Life Sciences LLC; Guardant Health Inc.; Tempus Labs; Oxford Nanopore Technologies; Foundation Medicine Inc.; NanoString Technologies Inc.; Exagen Inc.; Asuragen Inc.; Personal Genome Diagnostics; Precision Biologics Inc.; Strata Oncology; Genelex Corp; Invitae Corporation; Color Genomics; Helix OpCo LLC; 10x Genomics Inc.; Agena Bioscience Inc.; Natera Inc.; Becton Dickinson and Company; PerkinElmer Inc.; Sophia Genetics; Genomic Vision; Personalis Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Personalized Medicine market report include:- Bayer AG
- Novartis AG
- Thermo Fisher Scientific Inc.
- GlaxoSmithKline plc
- AstraZeneca plc
- Abbott Laboratories
- Danaher Corporation
- Eli Lilly and Company
- Decode Genetics Inc.
- GE HealthCare Technologies Inc.
- Roche Diagnostics
- Genentech Inc.
- Biogen Inc.
- Illumina Inc.
- Qiagen N.V.
- Exact Sciences Corporation
- Myriad Genetics Inc.
- Verily Life Sciences LLC
- Guardant Health Inc.
- Tempus Labs
- Oxford Nanopore Technologies
- Foundation Medicine Inc.
- NanoString Technologies Inc.
- Exagen Inc.
- Asuragen Inc.
- Personal Genome Diagnostics
- Precision Biologics Inc.
- Strata Oncology
- Genelex Corp
- Invitae Corporation
- Color Genomics
- Helix OpCo LLC
- 10x Genomics Inc.
- Agena Bioscience Inc.
- Natera Inc.
- Becton Dickinson and Company
- PerkinElmer Inc.
- Sophia Genetics
- Genomic Vision
- Personalis Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 469.11 Billion |
| Forecasted Market Value ( USD | $ 733.27 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 41 |
